Page last updated: 2024-11-13
pretubulysin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
pretubulysin: from myxobacteria; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 44195319 |
CHEMBL ID | 3120620 |
SCHEMBL ID | 12193994 |
MeSH ID | M0577222 |
Synonyms (14)
Synonym |
---|
SCHEMBL12193994 |
CHEMBL3120620 |
pretubulysin |
pretubulysin-827 |
benzenepentanoic acid, .alpha.-methyl-.gamma.-(((2-((3r)-4-methyl-3-(methyl((2s,3s)-3-methyl-2-((((2r)-1-methyl-2-piperidinyl)carbonyl)amino)-1-oxopentyl)amino)pentyl)-4-thiazolyl)carbonyl)amino)-, (.alpha.s,.gamma.r)- |
pretubulysin d |
1174764-12-5 |
Q67GVO8JTM , |
(2s,4r)-2-methyl-4-(((2-((3r)-4-methyl-3-(methyl(n-(((2r)-1-methyl-2-piperidinyl)carbonyl)-l-isoleucyl)amino)pentyl)-1,3-thiazol-4-yl)carbonyl)amino)-5-phenylpentanoic acid |
benzenepentanoic acid, alpha-methyl-gamma-(((2-((3r)-4-methyl-3-(methyl((2s,3s)-3-methyl-2-((((2r)-1-methyl-2-piperidinyl)carbonyl)amino)-1-oxopentyl)amino)pentyl)-4-thiazolyl)carbonyl)amino)-, (alphas,gammar)- |
unii-q67gvo8jtm |
nsc-790139 |
nsc790139 |
Q27287058 |
Research Excerpts
Overview
Pretubulysin (PT) is a novel, synthetically accessible myxobacterial compound that acts as a tubulin-depolymerizing agent and inhibits cancer cell growth in vitro and in vivo. It is a bio-precursor of highly toxic tetrapeptide tubulysins.
Excerpt | Reference | Relevance |
---|---|---|
"Pretubulysin is a bio-precursor of highly toxic tetrapeptide tubulysins. " | ( Synthesis and Evaluation of Biological Properties of 2-Amino-thiazole-4-carboxamides: Amide Linkage Analogues of Pretubulysin. Fan, M; Ouyang, B; Qi, J; Wang, H; Wang, L; Yao, L, 2020) | 2.21 |
"Pretubulysin (PT) is a novel, synthetically accessible myxobacterial compound that acts as a tubulin-depolymerizing agent and inhibits cancer cell growth in vitro and in vivo. " | ( Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo. Fürst, R; Gellrich, D; Kazmaier, U; Kretzschmann, VK; Ullrich, A; Vollmar, AM; Zahler, S, 2014) | 2.15 |
"Pretubulysin is a natural product that is found in strains of myxobacteria in only minute amounts. " | ( Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy. Elnakady, YA; Herrmann, J; Kazmaier, U; Müller, R; Rohde, M; Ullrich, A; Vollmar, AM; Wiedmann, RM, 2012) | 3.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (11)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1070475 | Inhibition of tubulin polymerization in human MDA-MB-231 cells assessed as disruption of tubulin cytoskeleton at 10 nM after 24 hrs by Hoechst 33342 staining-based immunohistochemistry | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070459 | Induction of apoptosis in human CCRF-CEM VCR/R cells at 1 uM after 72 hrs by CellTitre-Blue assay relative to control | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1183884 | Cytotoxicity against human MONO-MAC-6 cells after 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15 | Melleolides induce rapid cell death in human primary monocytes and cancer cells. |
AID1070473 | Inhibition of tubulin polymerization in human T24 cells at 10 nM after 24 hrs by Hoechst 33342 staining-based immunohistochemistry | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070469 | Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase at 10 nM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 22%) | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070463 | Cytotoxicity against human MDA-MB-231 cells at 1 to 1000 nM after 72 hrs by CellTitre-Blue assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070471 | Cytotoxicity against human PBMC at 1 uM after 24 to 72 hrs by MTT assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070470 | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTitre-Blue assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070458 | Induction of apoptosis in human CCRF-CEM VCR/R cells at 2.5 uM after 72 hrs by CellTitre-Blue assay relative to control | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1070464 | Antimigratory activity against human MDA-MB-231 cells at 1 uM after 18 hrs by wound healing assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Simplified pretubulysin derivatives and their biological effects on cancer cells. |
AID1183890 | Cytotoxicity against human primary monocytes up to 1 uM after 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15 | Melleolides induce rapid cell death in human primary monocytes and cancer cells. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (18)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 15 (83.33) | 24.3611 |
2020's | 3 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |